SOPHiA GENETICS (SOPH) Q2 FY26 earnings call

SOPHiA GENETICS delivered strong Q2 FY26 results, marked by accelerating revenue growth, particularly in the US and liquid biopsy, and significant progress towards profitability. The company secured landmark companion diagnostic partnerships with AstraZeneca and a joint venture MOU with Memorial Sloan Kettering, reinforcing its strategy to become the AI platform for precision medicine. Management raised full-year revenue guidance while reaffirming its commitment to adjusted EBITDA breakeven by year-end and positive adjusted EBITDA in H2 2027, supported by a strong cash position.